Information Concerning Guarantor and Non-Guarantor Subsidiaries - Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	$ 126,902	$ 79,256
Purchases of property and equipment	(55,878)	(38,818)
Proceeds from sale of Peterson LOI	6,785	10,000
Investment in Gaylord Rockies joint venture	(31,944)
Increase in restricted cash and cash equivalents	(7,611)	(7,860)
Other investing activities	(1,900)	340
Net cash provided by (used in) investing activities	(90,548)	(36,338)
Net borrowings under credit facility	67,500	(246,000)
Repayments under term loan B	(2,000)	(2,000)
Repayment of note payable related to purchase of AC Hotel	(6,000)
Issuance of senior notes		400,000
Repurchase of Company stock for retirement	(24,811)
Repurchase of common stock warrants		(154,681)
Deferred financing costs paid		(10,723)
Payment of dividend	(74,648)	(62,070)
Proceeds from exercise of stock option and purchase plans	1,142	1,430
Payment of tax withholdings for share-based compensation	(3,087)	(3,646)
Other financing activities	(9)	(317)
Net cash provided by (used in) financing activities	(41,913)	(78,007)
Net change in cash and cash equivalents	(5,559)	(35,089)
Cash and cash equivalents - unrestricted, beginning of period	56,291	76,408
Cash and cash equivalents - unrestricted, end of period	50,732	41,319
Parent Guarantor [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	102,768	208,725
Purchases of property and equipment	(8,105)	(53)
Proceeds from sale of Peterson LOI	6,785	10,000
Net cash provided by (used in) investing activities	(1,320)	9,947
Repurchase of Company stock for retirement	(24,811)
Repurchase of common stock warrants		(154,681)
Payment of dividend	(74,648)	(62,070)
Proceeds from exercise of stock option and purchase plans	1,142	1,430
Payment of tax withholdings for share-based compensation	(3,087)	(3,646)
Net cash provided by (used in) financing activities	(101,404)	(218,967)
Net change in cash and cash equivalents	44	(295)
Cash and cash equivalents - unrestricted, beginning of period	23	392
Cash and cash equivalents - unrestricted, end of period	67	97
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	(60,725)	(140,988)
Net borrowings under credit facility	67,500	(246,000)
Repayments under term loan B	(2,000)	(2,000)
Repayment of note payable related to purchase of AC Hotel	(6,000)
Issuance of senior notes		400,000
Deferred financing costs paid		(10,723)
Net cash provided by (used in) financing activities	59,500	141,277
Net change in cash and cash equivalents	(1,225)	289
Cash and cash equivalents - unrestricted, beginning of period	1,578	1,001
Cash and cash equivalents - unrestricted, end of period	353	1,290
Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	12,326	398
Purchases of property and equipment	(12,497)	(387)
Other investing activities	28
Net cash provided by (used in) investing activities	(12,469)	(387)
Net change in cash and cash equivalents	(143)	11
Cash and cash equivalents - unrestricted, beginning of period	158	36
Cash and cash equivalents - unrestricted, end of period	15	47
Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	72,533	11,121
Purchases of property and equipment	(35,276)	(38,378)
Investment in Gaylord Rockies joint venture	(31,944)
Increase in restricted cash and cash equivalents	(7,611)	(7,860)
Other investing activities	(1,928)	340
Net cash provided by (used in) investing activities	(76,759)	(45,898)
Other financing activities	(9)	(317)
Net cash provided by (used in) financing activities	(9)	(317)
Net change in cash and cash equivalents	(4,235)	(35,094)
Cash and cash equivalents - unrestricted, beginning of period	54,532	74,979
Cash and cash equivalents - unrestricted, end of period	$ 50,297	$ 39,885